O'Connor Eibhlís M, Grealy Geraldine, McCarthy Jane, Desmond Alan, Craig Orla, Shanahan Fergus, Cashman Kevin D
School of Food and Nutritional Sciences, University College Cork,Cork,Republic of Ireland.
Department of Medicine,University College Cork,Cork,Republic of Ireland.
Br J Nutr. 2014 Oct 14;112(7):1163-74. doi: 10.1017/S0007114514001913. Epub 2014 Sep 2.
Although epidemiological findings support a role for vitamin K status in the improvement of bone indices in adult patients with Crohn's disease (CD), this needs to be confirmed in double-blind, randomised controlled trials (RCT) with phylloquinone (vitamin K1). By conducting two RCT, the present study aimed to first establish whether supplementation with 1000 μg of phylloquinone daily near-maximally suppresses the percentage of undercarboxylated osteocalcin in serum (%ucOC; marker of vitamin K status) in adult patients with CD currently in remission as it does in healthy adults and second determine the effect of supplementation with phylloquinone at this dose for 12 months on the indices of bone turnover and bone mass. The initial dose-ranging RCT was conducted in adult patients with CD (n 10 per group) using 0 (placebo), 1000 or 2000 μg of phylloquinone daily for 2 weeks. In the main RCT, the effect of placebo v. 1000 μg vitamin K/d (both co-administered with Ca (500 mg/d) and vitamin D3 (10 μg/d)) for 12 months (n 43 per group) on the biochemical indices of bone turnover (determined by enzyme immunoassay) and bone mass (determined by dual-energy X-ray absorptiometry) were investigated. At baseline, the mean %ucOC was 47 %, and this was suppressed upon supplementation with 1000 μg of phylloquinone daily ( - 81 %; P< 0·01) and not suppressed further by 2000 μg of phylloquinone daily. Compared with the placebo, supplementation with 1000 μg of phylloquinone daily for 12 months had no significant effect (P>0·1) on bone turnover markers or on the bone mass of the lumbar spine or femur, but modestly increased (P< 0·05) the bone mass of the total radius. Despite near maximal suppression of serum %ucOC, supplementation with 1000 μg of phylloquinone daily (with Ca and vitamin D3) had no effect on the indices of bone health in adult CD patients with likely vitamin K insufficiency.
尽管流行病学研究结果支持维生素K状态在改善成年克罗恩病(CD)患者骨指标方面发挥作用,但这需要在使用叶绿醌(维生素K1)的双盲随机对照试验(RCT)中得到证实。通过开展两项RCT,本研究旨在首先确定,对于目前处于缓解期的成年CD患者,每日补充1000μg叶绿醌是否能像在健康成年人中那样最大程度地抑制血清中未羧化骨钙素的百分比(%ucOC;维生素K状态的标志物),其次确定以该剂量补充叶绿醌12个月对骨转换指标和骨量的影响。初始剂量范围RCT在成年CD患者中进行(每组n = 10),每日使用0(安慰剂)、1000或2000μg叶绿醌,持续2周。在主要RCT中,研究了安慰剂与每日1000μg维生素K(均与钙(500mg/d)和维生素D3(10μg/d)联合使用)持续12个月(每组n = 43)对骨转换生化指标(通过酶免疫测定法测定)和骨量(通过双能X线吸收法测定)的影响。在基线时,平均%ucOC为47%,每日补充1000μg叶绿醌后该指标受到抑制(-81%;P<0.01),而每日补充2000μg叶绿醌并未进一步抑制。与安慰剂相比,每日补充1000μg叶绿醌持续12个月对骨转换标志物或腰椎或股骨的骨量没有显著影响(P>0.1),但使总桡骨骨量适度增加(P<0.05)。尽管血清%ucOC几乎被最大程度抑制,但每日补充1000μg叶绿醌(与钙和维生素D3一起)对可能存在维生素K不足的成年CD患者的骨健康指标没有影响。